The correlation between MFAP4 and recurrence and clinical outcome of atrial fibrillation after radiofrequency catheter ablation

• 作者: Xian-Lin Zhang Xiang-Wen Hu Qiao Lu Ye-Yun Zhang Yu-Li Huang Ling Xuan Xiao-Jun Shi Hong-Ju Wang Heng Zhang
• 来源期刊: 海南医科大学学报（英文版）
• 年，卷（期）: 2021,（15）
• 所属期刊栏目: Original article
• 页码范围: 15-19
• 页数: 5页
• 语种: 英文

摘要

Objective: To investigate the correlation between Microfibrillar-associated protein 4 (MFAP4) and recurrence and clinical outcome of atrial fibrillation (AF) after radiofrequency catheter ablation (RFCA). Methods: A total of 101 patients with AF admitted to our department from December 2018 to January 2020 were treated with RFCA. The average follow-up period was (11.91 ± 0.38) months. They were divided into recurrence group and non-recurrence group according to whether they had recurrence of AF. The levels of MFAP4, transforming growth factor-β1 (TGF-β1), cardiac ultrasound indexes, body mass index (BMI) and major cardio-cerebral vascular events were compared between the two groups. The receiver operating characteristic (ROC) curve was drawn to analyze the predictive value of MFAP4 for recurrence of AF after RFCA. Results: The levels of MFAP4, TGF-β1, left atrial diameter (LAD) and BMI in the recurrent group were higher than those in the non-recurrent group (P < 0.05). The left ventricular ejection fraction (LVEF) in the recurrent group was lower than that in the non-recurrent group (P < 0.05). The levels of MFAP4, TGF-β1 and LAD in the patients of recurrent paroxysmal AF and persistent AF after RFCA were higher than those in the respective non-recurrent patients (P < 0.05). MFAP4 was positively correlated with TGF - β 1 and LAD (P < 0.05). Logistic regression analysis showed that MFAP4, TGF-β1, and LAD were independent risk factors for recurrence of AF after RFCA. The ROC curve analysis showed that the area under the ROC curve of MFAP4 for predicting recurrence of AF after RFCA was 0.888 (P = 0.000), and the optimal cut-off value was 19.295ng/ml, with a sensitivity of 77.3％ and a specificity of 77.2％. The incidence of readmission and total adverse events in recurrence group was significantly higher than that in non-recurrence group (P < 0.05). Conclusions: MFAP4 was significantly increased in patients with recurrence after RFCA of AF, which was one of the independent risk factors for recurrence after RFCA of AF, and had certain clinical application value.